2017 EAACI免疫治疗指南:变应性鼻结膜炎

2017-09-23 欧洲变应性反应与临床免疫学会 Allergy. 2017 Sep 23.

2017年9月,欧洲变应性反应与临床免疫学会(EAACI)发布了变应性鼻结膜炎免疫治疗指南,变应性鼻结膜炎是一种主要影响鼻和眼睛的变态反应性疾病,本文主要针对变应性鼻结膜炎的免疫治疗提供指导建议。

中文标题:

2017 EAACI免疫治疗指南:变应性鼻结膜炎

英文标题:

EAACI Guidelines on Allergen Immunotherapy: Allergic Rhinoconjunctivitis.

发布日期:

2017-09-23

简要介绍:

2017年9月,欧洲变应性反应与临床免疫学会(EAACI)发布了变应性鼻结膜炎免疫治疗指南,变应性鼻结膜炎是一种主要影响鼻和眼睛的变态反应性疾病,本文主要针对变应性鼻结膜炎的免疫治疗提供指导建议。

 

拓展指南:免疫相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2017 EAACI免疫治疗指南:变应性鼻结膜炎)] GetToolGuiderByIdResponse(projectId=1, id=667281c001503556, title=2017 EAACI免疫治疗指南:变应性鼻结膜炎, enTitle=EAACI Guidelines on Allergen Immunotherapy: Allergic Rhinoconjunctivitis., guiderFrom=Allergy. 2017 Sep 23., authorId=null, author=, summary=2017年9月,欧洲变应性反应与临床免疫学会(EAACI)发布了变应性鼻结膜炎免疫治疗指南,变应性鼻结膜炎是一种主要影响鼻和眼睛的变态反应性疾病,本文主要针对变应性鼻结膜炎的免疫治疗提供指导建议。 , cover=, journalId=null, articlesId=null, associationId=615, associationName=欧洲变应性反应与临床免疫学会, associationIntro=EAACI是一个集临床医生、科研人员及过敏性疾病专家于一体的协会组织,致力于改善受过敏性疾病困扰的患者健康。该协会目前拥有超过6,800名个人成员及41个欧洲国家社团,是欧洲过敏性疾病所有方面知识的主要来源。, copyright=0, guiderPublishedTime=Sat Sep 23 00:00:00 CST 2017, originalUrl=, linkOutUrl=, content=<P>2017年9月,欧洲变应性反应与临床免疫学会(EAACI)发布了变应性鼻结膜炎免疫治疗指南,变应性鼻结膜炎是一种主要影响鼻和眼睛的变态反应性疾病,本文主要针对变应性鼻结膜炎的免疫治疗提供指导建议。 </P> <P> </P>拓展指南:<strong>与<font color=red>免疫</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=66f651c001a9599c" title="2017 EAACI免疫治疗指南:过敏的预防" target=_blank>2017 EAACI免疫治疗指南:过敏的预防</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=38f9a1c001a94228" title="2016版美国《成人和青少年人类免疫缺陷病毒感染者机会性感染防治指南》结核病部分解读" target=_blank>2016版美国《成人和青少年人类免疫缺陷病毒感染者机会性感染防治指南》结核病部分解读</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=79b6b1c001a838e8" title="中国自身免疫性脑炎诊治专家共识" target=_blank>中国自身免疫性脑炎诊治专家共识</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=52c2d1c001a834a0" title="中国人类免疫缺陷病毒感染的特殊群体抗病毒治疗专家共识" target=_blank>中国人类免疫缺陷病毒感染的特殊群体抗病毒治疗专家共识</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=2fd9a1c001a811b5" title="2017 BCSH指南:药物引起的免疫以及二次免疫溶血性贫血的管理" target=_blank>2017 BCSH指南:药物引起的免疫以及二次免疫溶血性贫血的管理</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E5%85%8D%E7%96%AB" target=_blank>有关免疫更多指南</a></ul>, tagList=[TagDto(tagId=60303, tagName=变应性鼻结膜炎)], categoryList=[CategoryDto(categoryId=15, categoryName=风湿免疫科, tenant=100), CategoryDto(categoryId=30, categoryName=耳鼻咽喉科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=2, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4623, appHits=167, showAppHits=0, pcHits=3652, showPcHits=1378, likes=136, shares=6, comments=2, approvalStatus=1, publishedTime=Wed Oct 04 11:22:04 CST 2017, publishedTimeString=2017-09-23, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Wed Oct 04 11:22:04 CST 2017, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 03:55:06 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2017 EAACI免疫治疗指南:变应性鼻结膜炎)])
2017 EAACI免疫治疗指南:变应性鼻结膜炎
下载请点击:
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=255978, encodeId=38622559e86e, content=想要的.谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/c9349b9bcd901b026bd750f7335f78f1.jpg, createdBy=13b02179645, createdName=曾超军, createdTime=Thu Oct 26 00:23:04 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=250352, encodeId=2d4525035274, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Wed Oct 04 18:35:59 CST 2017, time=2017-10-04, status=1, ipAttribution=)]
    2017-10-26 曾超军

    想要的.谢谢

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=255978, encodeId=38622559e86e, content=想要的.谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/c9349b9bcd901b026bd750f7335f78f1.jpg, createdBy=13b02179645, createdName=曾超军, createdTime=Thu Oct 26 00:23:04 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=250352, encodeId=2d4525035274, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Wed Oct 04 18:35:59 CST 2017, time=2017-10-04, status=1, ipAttribution=)]
    2017-10-04 1e0e5697m83(暂无匿称)

    henhao

    0